Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer
- 85 Downloads
Background: The objective was to determine the impact of multicentric breast cancer on recurrence and survival and to evaluate the current tumor, node, metastasis staging system recommendations for multicentricity in the breast.
Methods: This study included 284 nonpregnant patients with T1-2, N0-1, M0 breast cancer, without previous cancer, who were treated by modified radical mastectomy followed by doxorubicin-based adjuvant chemotherapy. Clinical and pathological data were collected retrospectively and survival was calculated from the date of initial diagnosis using the Kaplan-Meier method.
Results: The median follow-up time was 8 years (range, 0.3–24.0), and the median age was 47 years (range, 23–76). The median clinical size of the index tumor was 2.5 cm. In 17% of patients, the clinical nodal status was N1. In 84% of patients, pathology of the index lesion was invasive ductal ± in situ. Multicentric breast cancer was detected in 60 patients (21%): 30 patients with two lesions, 13 patients with three lesions, and 17 patients with four or more lesions. Locoregional recurrence, contralateral breast cancer, distant metastasis, and survival (disease-specific and disease-free) were similar in both groups of multicentric versus unicentric breast tumors. There was a significant difference between groups in estrogen receptor and axillary lymph node positivity, but these did not contribute significantly to outcome on multivariate analysis.
Conclusions: Multicentricity does not increase the risk of poor outcomes in patients with early-stage breast cancer. This supports the current recommendations of the tumor, node, metastasis staging system that tumor size should be based on the diameter of the largest lesion in patients with multicentric breast cancer.
Key WordsBreast neoplasms Multicentric Multiple primary Local recurrence Survival
Unable to display preview. Download preview PDF.
- 3.Cheatle GL, Cutler M.Tumors of the Breast: Their Pathology, Symptoms, Diagnoses and Treatment. Philadelphia: JB Lippincott, 1931.Google Scholar
- 5.McDivitt RW. Breast cancer multicentricity. In: McDivitt RW, Oberman HA, Ozzello L, et al., eds.The Breast. Baltimore: Williams & Wilkins, 1984:139–48.Google Scholar
- 11.American Joint Committee on Cancer. Breast. In:AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997:127–33.Google Scholar
- 12.Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guérin and with or without irradiation in operable breast cancer: a prospective randomized trial.Cancer 1984;53:384–9.PubMedCrossRefGoogle Scholar
- 15.Buzdar AU, Hortobagyi GN, Kau SW, et al. Breast cancer adjuvant therapy at the M.D. Anderson Cancer Center—results of four prospective studies. In: Salmon SE, ed.Adjuvant Therapy of Cancer VII. Philadelphia: JB Lippincott, 1993:220–5.Google Scholar
- 16.Kemp BL. Breast specimen evaluation. In: Singletary SE, ed.Breast Cancer. (M.D. Anderson Solid Tumor Oncology Series.) New York: Springer-Verlag, 1999:120–31.Google Scholar
- 17.Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958;185:1457–81.Google Scholar
- 18.Cox DR. Regression models and life-tables.J Royal Stat Soc 1972;34:187–220.Google Scholar